basiliximab + belatacept + mycophenolate mofetil

**basiliximab + belatacept + mycophenolate mofetil** is a pharmaceutical combination regimen primarily used for the prophylaxis of organ rejection in adult kidney transplant recipients seropositive for Epstein-Barr virus (EBV)[1][3][5][7]. - **Basiliximab** is a chimeric monoclonal antibody targeting CD25 (the alpha-chain of the interleukin-2 receptor) on activated T cells, preventing IL-2-mediated T-cell activation and proliferation, thereby reducing immune responses against the transplanted organ[2][4][6][8]. - **Belatacept** is a recombinant fusion protein (CTLA4-IgG1) that binds to CD80 and CD86 on antigen-presenting cells, blocking costimulatory signals required for T-cell activation. This prevents T-cell-mediated immune responses[1][5][7]. - **Mycophenolate mofetil** is a small molecule immunosuppressant that inhibits inosine monophosphate dehydrogenase, suppressing lymphocyte proliferation by blocking de novo guanosine nucleotide synthesis[1][3][7]. This regimen is often administered with corticosteroids during induction and maintenance phases in kidney transplantation to optimize immune suppression while minimizing toxicity.[1][3][7]

Other names

basiliximab + belatacept + mycophenolate mofetil